Stock Market Outlook Based on Algorithmic Trading: Returns up to 47.00% in 14 Days

Package Name: Risk-Conscious - Aggressive Stocks Forecast
Recommended Positions: Long
Forecast Length: 14 Days (01/02/2017 - 01/16/2017)
I Know First Average: 6.44%

Read The Full Forecast

IKForecast_top_10_aggressive_02_Jan_2017 14 DAYS LONG until 16 Jan long

Market Forecast Based on Big Data Analytics: Returns up to 72.49% in 3 Days

Package Name: High Volume Stocks
Recommended Positions: Long
Forecast Length: 3 Days (01/08/2017 - 01/11/2017)
I Know First Average: 8.15%

Read The Full Forecast

Best Short Term Stocks

High Risk High Reward Stocks Based on Big Data: Returns up to 20% in 3 Days

Package Name: Risk-Conscious - Aggressive Stocks Forecast
Recommended Positions: Long
Forecast Length: 3 Days (01/02/2017 - 01/05/2017)
I Know First Average: 9.88%

Read The Full Forecast

High Risk High Reward Stocks

Using Genetic Algorithms to Forecast Financial Markets : Returns up to 34.00% in 7 Days

Package Name: Risk-Conscious - Aggressive Stocks Forecast
Recommended Positions: Long
Forecast Length: 7 Days (01/01/2017 - 01/08/2017)
I Know First Average: 7.37%

Read The Full Forecast

Using Genetic Algorithms to Forecast Financial Markets

Stock Scanner Based on Pattern Recognition: Returns up to 22.06% in 3 Days

Package Name: Risk-Conscious - Aggressive Stocks Forecast
Recommended Positions: Long
Forecast Length: 3 Days (01/01/2017 - 01/04/2017)
I Know First Average: 9.37%

Read The Full Forecast

Stock Scanner

Stock Market Outlook Based on Big Data: Returns up to 29.04% in 7 Days

52 Week Low Stocks Package Name: 52 Week Low Stocks
Recommended Positions: Short
Forecast Length: 7 Days (11/01/2016 - 11/08/2016)
I Know First Average: 8.94%

Read The Full Forecast

Stock Market Outlook

Valeant Pharmaceuticals Stock Prediction: The Road to Recovery

Samantha Fischler is a Financial Analyst at I Know First. She is currently a candidate for her bachelor’s degree in Accounting with a Concentration in Finance at Binghamton University.

  • Valeant Pharmaceuticals makes major changes to its leadership
  • Since October 2015, Valeant has been under investigation due to its connection to Philidor
  • Valeant is currently being sued by T. Rowe Price Group who allege that Valeant engaged in fraudulent activities that cost investor billions of dollars
  • The company reported losses in Q2 2016
  • Valeant is relaunching temporarily discontinued drugs and releasing new drugs
  • I Know First is currently bullish on VRX

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here